SEC Form 4 · accession 0001193125-26-335617
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Maduck
Officer — See Remarks
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 5:51 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2026 | M | 20,305 | $8.27 | A | 30,060 | D | |
| Common StockF3,F1 | Aug 3, 2026 | S | 20,305 | $114.7045 | D | 9,755 | D | |
| Common StockF4 | holding | — | — | — | 5,147 | I | See Footnote | |
| Common StockF5 | holding | — | — | — | 20,570 | I | See Footnote | |
| Common StockF6 | holding | — | — | — | 40,000 | I | See Footnote | |
| Common StockF7 | holding | — | — | — | 34,000 | I | See Footnote | |
| Common StockF8 | holding | — | — | — | 10,000 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F9 | $8.27 | Aug 3, 2026 | M | 20,305 | D | — | Feb 10, 2027 | Common Stock | 20,305 | 96,681 | D |
Explanation of responses
- F1Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.49 to $115.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- F5Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
- F6Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F7Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F8Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F9Fully exercisable.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.